Non-responders to this combination therapy had higher levels of oestrone and dehydroepiandrosterone sulphate whilst on treatment than responders, confirming previous observations in patients treated with aminoglutethimide + hydrocortisone.
Summary By analogy with combination chemotherapy, endocrine agents with different mechanisms of action have been combined in the treatment of patients with advanced breast cancer. The clinical use of tamoxifen + aminoglutethimide + hydrocortisone showed no clinical benefit over the individual use of tamoxifen or aminoglutethimide + hydrocortisone. The endocrine changes occurring in postmenopausal patients as a consequence of their treatment with tamoxifen+aminoglutethimide+hydrocortisone have been examined. Suppression of gonadotrophin and oestrogen levels and increased levels of sex hormone binding globulin were observed. These changes might be expected to be of benefilt in the treatment of advanced breast cancer, and do not explain the lack of clinical benefit in combining the treatments.
Non-responders to this combination therapy had higher levels of oestrone and dehydroepiandrosterone sulphate whilst on treatment than responders, confirming previous observations in patients treated with aminoglutethimide + hydrocortisone.
There are now several options for the medical endocrine treatment of advanced breast cancer in postmenopausal women (Stoll, 1981) . Response to these individual agents occurs in about one third of unselected patients. The incidence of response can be increased by patient selection on the basis of oestrogen receptor analyses (McGuire, 1980) . It is clear that a few patients will respond to one of these agents having failed to respond to another and, in addition, some patients who have relapsed after responding to one agent may show a second response to another (Smith et al., 1982 
Patients and methods

Patients
Forty-six patients were studied from a previously described clinical trial (Smith et al., 1982 (Hayward et al., 1977) . All (Harris et al., 1983a) ; DHAS, (Harris, et al., 1982) ; androstenedione, (Dowsett et al., 1984) ; prolactin, (Dowsett et al., 1983) ]. Cross-reaction of tamoxifen in the oestradiol and oestrone assays was 10-4% and 10-3% respectively. Sex hormone binding globulin (SHBG) binding capacity was measured according to the method of Iqbal and Johnson (Iqbal & Johnson, 1977) . Luteinizing hormone (LH) and FSH were measured by double antibody radioimmunoassay using the Chelsea LH/FSH Radioimmunoassay Kit, which is used by over 25 centres in the United Kingdom (Ferguson et al., 1982) .
All samples from the same patient were analysed in the same batch.
Analysis of results
In some patients multiple samples were available for analysis but for statistical comparison the mean of the results was taken. Differences between pretreatment and on-treatment samples were analyzed by t-tests on paired data only, but the means given include data from patients in which one or other sample was missing. Differences between responders and non-responders were analyzed by unpaired t-tests.
Results
Effect of treatment on hormone levels: Pretreatment hormone levels were compared with the levels found between 1 and 4 months after starting treatment (Table I) . Mean levels of LH, FSH, oestrone, oestradiol and DHAS were suppressed on treatment but there were no significant differences between pretreatment and ontreatment levels of prolactin or androstenedione. The mean percentage suppression was for LH 25%, FSH 25%, oestrone 42%, oestradiol 71% and DHAS 80%. SHBG levels on treatment were significantly higher than pretreatment levels showing a mean percentage increase of 66%.
Differences between responders and non-responders:
Those patients having stable disease on treatment numbered only 5 and were therefore excluded from the following comparisons. The pretreatment levels of each hormone were compared between those patients who responded and those with progressive disease (Table IIA) . The only significant difference found was that the pretreatment level of DHAS was lower in responders than in non-responders (P= 0.022).
Comparison during treatment of responders and non-responders (Table IIB) showed a significantly lower level of oestrone in responders than in nonresponders (P= 0.004). No relationship was found between oestrone levels and the incidence of metastatic disease in particular sites. There was also a lower mean level of DHAS in responders, which was of marginal statistical significance (P '0.05). No significant correlation was found in this study between patient weight and either pretreatment or on-treatment levels of either DHAS or oestrone. There were no differences between responders and non-responders in the effects of treatment on hormone levels except in androstenedione levels which were significantly suppressed in responders (P=0.016, n= 14). In contrast, non-responders had a higher mean level of androstenedione ontreatment than before treatment, though high between-patient variability led to the difference being statistically non-significant.
Discussion
The major mechanism by which patients with advanced breast cancer respond to endocrine agents is thought to be by the suppression of oestrogenstimulated tumour growth (Stoll, 1981) . Tamoxifen is thought to act by blocking the interaction of oestrogen with oestrogen receptors (McGuire, 1980) whilst aminoglutethimide is believed to act by suppressing oestrogen synthesis (Santen et al., 1978) . It is clear, however, that some patients who fail to respond to one of these agents, will respond to the other (Smith et al., 1982) . Also many patients who relapse subsequent to an initial response to one of the drugs will go on to show a second response to the other (Smith et al., 1982) . It is possible therefore that by combining the two drugs, a greater proportion of patients might respond and the response might be of longer duration than with the individual agents given separately. However, a clinical evaluation of the combination showed no significant improvement over the individual agents in response rate or response duration . The combination may therefore be disadvantageous in that the opportunity for sequential treatment for a second response after relapse from first-line treatment is lost.
The endocrine effects of the combination were largely those which might be expected from the known action of the individual agents in postmenopausal women. Gonadotrophin levels were suppressed and SHBG levels were increased. Tamoxifen has been found to cause such typically oestrogenic changes (Coombes et al., 1982; Willis et al., 1977; Sakai et al., 1978) whilst aminoglutethimide+hydrocortisone has little effect on gonadotrophins but may also increase SHBG levels (Harris et al., 1983a) . Oestrone, oestradiol and DHAS levels were suppressed to levels similar to those found in our previous studies of aminoglutethimide + hydrocortisone (Harris et al., 1983a, b) . Tamoxifen would not be expected to affect the levels of these hormones (Coombes et al., 1982; Golder et al., 1976) , though it has been suggested by one study that oestradiol levels were increased by tamoxifen (Willis et al., 1977) . Any such effect clearly did not overcome the suppressive effects of aminoglutethimide + hydrocortisone in this study. The changes in hormone levels associated with tamoxifen may be considered in terms of benefit or detriment to the suppression of oestrogen levels by aminoglutethimide. The observed fall in gonadotrophin levels may be of some benefit, but is unlikely to be of importance, since little oestrogen is derived from the ovary in postmenopausal women (Vermeulen, 1976) . Increased SHBG levels result in decreases in the unbound, biologically active fraction of oestradiol (Anderson, 1974) . These two effects would therefore be expected to add to the suppression of oestrogen-stimulated tumour growth, and cannot explain the lack of clinical benefit from combining the agents.
Tamoxifen shows both oestrogenic and antioestrogenic effects (Clark & Peck, 1979; Rochefort et al., 1983; Wakeling et al., 1983) . The balance of these effects varies between tissues (Clark & Peck, 1979) and even within the same cell (Rochefort et al., 1983) . In the immature rat uterus tamoxifen shows greater oestrogenic activity in the presence of low concentrations of oestrogen (Wakeling et al., 1983) (Brodie et al., 1983) .
DHAS levels were higher in non-responders than responders both before treatment and during treatment.
In two earlier studies of aminoglutethimide + hydrocortisone in advanced breast cancer no difference in pretreatment levels of DHAS was observed between responders and nonresponders (Harris et al., 1983a; Santen et al., 1982) . However, a similar difference between responders and non-responders was observed in ontreatment samples from one of these studies (Santen et al., 1982 The difference between responders and nonresponders in pretreatment DHA-S levels is less easily explained. We could find no evidence for a weight-related excess of DHA-S in the nonresponders (Feher & Halmy, 1975 
